

PFIZER INC  
Form 8-K  
December 14, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): December 14, 2017**

**PFIZER INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**235 East 42nd Street**

**1-3619**  
**(Commission**

**File Number)**

**13-5315170**  
**(I.R.S. Employer**

**Identification No.)**

**10017**

**New York, New York**  
**(Address of principal executive offices)** **(Zip Code)**  
**Registrant's telephone number, including area code: (212) 733-2323**

**Not Applicable**

**(Former Name or Former Address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 8.01 Other Events**

On December 14, 2017, Pfizer Inc. (the Company ) announced that it had priced its previously announced (i) private offer (the Exchange Offer ) to exchange any and all of its outstanding £1,500,000,000 6.500 per cent. Notes due 2038 (the 2038 Notes ) for newly issued debt securities of the Company, and (ii) offer to purchase (the Tender Offer and, together with the Exchange Offer, the 2038 Notes Offers ) for cash any and all of its outstanding 2038 Notes from holders thereof.

A copy of the Company s press release announcing the pricing of the 2038 Notes Offers is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

The 2038 Notes Offers will expire at 5:00 p.m. (New York time) on December 14, 2017.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Exhibit Description</b>
99.1	Press Release of Pfizer Inc., dated December 14, 2017

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Exhibit Description</b>
99.1	<u>Press Release of Pfizer Inc., dated December 14, 2017</u>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PFIZER INC.

By: /s/ Margaret M. Madden  
Margaret M. Madden  
Senior Vice President and Corporate  
Secretary  
Chief Governance Counsel

Dated: December 14, 2017